Structure of futibatinib (Tas-120)

oral irreversible FGFR1-4 inhibitor

in Ph. I-III trials for FGFR+ advanced tumors

from structure-based design

Cancer Res., Sep. 24, 2020

Taiho Pharmaceutical, Tokyo, JP

TAS-120 (futibatinib) is an orally available, irreversible FGFR1-4 inhibitor with a unique binding mode, targeting a unique cysteine in the P-loop of the FGFRs, rather than the Cys in the…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.